Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China

C.L. Hou, X.R. Ma, Y. Zang, F.J. Jia, Y.Q. Lin, H.F.K. Chiu, Gabor Ungvari, C.H. Ng, B.L. Zhong, X.L. Cao, Y. Li, M.Y. Cai, Y.T. Xiang

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Objective: In China, maintenance treatment for clinically stable patients with schizophrenia is usually provided by primary care physicians, but their prescribing patterns have not been studied. This study examined the frequency as well as demographic and clinical correlates of antipsychotic polypharmacy (APP) and its impact on quality of life (QOL) in patients with schizophrenia treated in primary care in China. Method: A total of 623 community-dwelling patients from 18 randomly selected primary care services were interviewed. Patients' socio-demographic and clinical characteristics, including number of hospitalizations, antipsychotic drug-induced side effects, and QOL were recorded using a standardized protocol and data collection procedure. Results: The rate of APP prescription was 31% (193/623). Of the patients on APP, 89.6% received 2 antipsychotics, 10.4% received 3 or more antipsychotics. Clozapine (35.6%) was the most commonly prescribed second generation antipsychotic (SGA), while perphenazine (17.8%) was the most commonly prescribed first generation antipsychotic (FGA). Multiple logistic regression analyses revealed that patients on APP were more likely to receive SGAs and anticholinergics, had fewer hospitalizations, younger age of onset, and higher doses of antipsychotics. There were no significant differences between the two groups in any of the QOL domains. Conclusions: Approximately a third of Chinese patients with schizophrenia in primary care receive APP. Further examination of the rationale and appropriateness of APP and its alternatives is warranted.
    Original languageEnglish
    Pages (from-to)36-42
    JournalInternational Journal of Clinical Pharmacology and Therapeutics
    Volume54
    Issue number1
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China'. Together they form a unique fingerprint.

  • Cite this